{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:57:52Z","timestamp":1791320272731,"version":"4.3.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5-6","funder":[{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","award":["Zirovich0002"],"award-info":[{"award-number":["Zirovich0002"]}],"id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Botulinum toxin type A (BoNT\/A) is an approved treatment for chronic migraine and has been shown to be effective in reducing number, days, and severity of headache in other headache disorders. Whether botulinum toxin is a safe and effective treatment specifically for post-traumatic headache (PTH), however, is unknown. This study sought to determine whether treatment with BoNT\/A improved symptoms of PTH in military veterans.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Forty subjects with PTH were randomized to receive treatment of either BoNT\/A or a saline placebo. Sixteen weeks post-treatment or at return to baseline headache severity, subjects were crossed over to receive treatment with the other medication than previously treated with in the first session. Subjects recorded number of headaches, number of headache days, and headache pain severity in daily diaries. Outcome measures included change in the weekly number of headaches, number of headache days per week, and headache pain severity compared to baseline, and the change in number of headaches and number of headaches days at baseline compared to the rating scores averaged across weeks 6\u201311.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The number of headaches per week significantly decreased by 2.24 (43.3%) with BoNT\/A treatment (P\u2009&amp;lt;\u2009.001) and significantly increased by 1.28 (35.1%) with placebo (P\u2009=\u2009.02) at the end of the 16 weeks and the difference between groups was also significant (P\u2009&amp;lt;\u2009.001). The number of headache days per week also significantly decreased by 2.24 (44.4%) at the end of 16 weeks with BoNT\/A treatment (P\u2009&amp;lt;\u2009.001), was not significantly changed with placebo, and the difference between the two groups was significant (P\u2009&amp;lt;\u2009.001). Both the change in number of headaches and number of headache days averaged across weeks 6\u201311 compared to baseline were significantly decreased in the BoNT\/A group (1.6 and 1.4, respectively) compared to a significant increase of 0.3 in number of weekly headaches and a nonsignificant decrease of 0.1 in number of headache days for the placebo group (P\u2009=\u2009.048 and P\u2009=\u2009.005, respectively). Headache pain severity was significantly reduced by 0.06 with botulinum toxin treatment (P\u2009=\u2009.02) and was not significantly increased by 0.04 in the placebo group with a significant difference between groups (P\u2009=\u2009.006).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Treatment with BoNT\/A clinically and significantly improved the frequency and pain severity of PTH compared to placebo in military veterans. Limitations of the study include subject dropout, adherence to documenting variables daily in the dairy, and only one treatment of BoNT\/A. Strengths include the cross-over study design, which demonstrated that BoNT\/A was effective regardless of treatment order. This dataset is the first prospective study to evaluate BoNT\/A as an intervention for symptoms of PTH and provides evidence that larger-scale and multiple treatment studies evaluating BoNT\/A for this headache type are warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/milmed\/usaa391","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T03:54:49Z","timestamp":1607313289000},"page":"493-499","source":"Crossref","is-referenced-by-count":37,"title":["Botulinum Toxin Type A for the Treatment of Post-traumatic Headache: A Randomized, Placebo-Controlled, Cross-over Study"],"prefix":"10.1093","volume":"186","author":[{"suffix":"MD","given":"Milena D","family":"Zirovich","sequence":"first","affiliation":[{"name":"Physical Medicine and Rehabilitation Service, VA Greater Los Angeles Healthcare Service, Los Angeles, CA 90073, USA"},{"name":"Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"MD","given":"Sanjog S","family":"Pangarkar","sequence":"additional","affiliation":[{"name":"Physical Medicine and Rehabilitation Service, VA Greater Los Angeles Healthcare Service, Los Angeles, CA 90073, USA"},{"name":"Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"MD","given":"Christina","family":"Manh","sequence":"additional","affiliation":[{"name":"Physical Medicine and Rehabilitation Service, VA Greater Los Angeles Healthcare Service, Los Angeles, CA 90073, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"MS","given":"Lucia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90024, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"MS","given":"Sitaram","family":"Vangala","sequence":"additional","affiliation":[{"name":"Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90024, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"PhD","given":"David A","family":"Elashoff","sequence":"additional","affiliation":[{"name":"Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90024, USA"},{"name":"Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095, USA"},{"name":"Clinical Translational Science Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90024, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"MD, MPH","given":"Ifeoma Stella","family":"Izuchukwu","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA"},{"name":"Internal Medicine Service, VA Greater Los Angeles Healthcare Service, Los Angeles, CA 90073, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"issue":"4","key":"2021050313323209200_R1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cnur.2010.06.003","article-title":"Traumatic brain injury in Operation Enduring Freedom\/Operation Iraqi Freedom: a primer","volume":"45","author":"Fabrizio","year":"2010","journal-title":"Nurs Clin North Am"},{"key":"2021050313323209200_R2","volume-title":"Author is Department of Defense (DoD) Worldwide Numbers for TBI"},{"issue":"6","key":"2021050313323209200_R3","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/head.12123","article-title":"Post-traumatic headaches in civilians and military personnel: a comparative, clinical review","volume":"53","author":"Theeler","year":"2013","journal-title":"Headache"},{"issue":"Suppl. 1","key":"2021050313323209200_R4","first-page":"1","article-title":"The International Classification of Headache Disorders","volume":"24","author":"Headache Classification Committee of the International Headache Society","year":"2004","journal-title":"Cephalalgia"},{"issue":"1","key":"2021050313323209200_R5","first-page":"1","article-title":"The International Classification of Headache Disorders","volume":"38","author":"Headache Classification Committee of the International Headache Society","year":"2018","journal-title":"Cephalalgia"},{"issue":"10 Suppl 2","key":"2021050313323209200_R6","first-page":"S406","article-title":"Headache management in concussion and mild traumatic brain injury","volume":"3","author":"Lucas","year":"2001","journal-title":"Pm R"},{"issue":"2","key":"2021050313323209200_R7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1468-2982.2004.00818.x","article-title":"Chronic post-traumatic headache\u2014a clinical analysis in relation to the international headache classification","volume":"25","author":"Baandrup","year":"2005","journal-title":"Cephalalgia"},{"issue":"7","key":"2021050313323209200_R8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"issue":"7","key":"2021050313323209200_R9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"issue":"6","key":"2021050313323209200_R10","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"issue":"2","key":"2021050313323209200_R11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0733-8635(03)00105-0","article-title":"Botulinum neurotoxin for the treatment of migraine and other primary headache disorders","volume":"22","author":"Blumenfeld","year":"2004","journal-title":"Dermatol Clin"},{"key":"2021050313323209200_R12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10194-005-0222-x","article-title":"Headache and botulinum toxin","volume":"6","author":"Porta","year":"2005","journal-title":"J Headache Pain"},{"key":"2021050313323209200_R13","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.3390\/toxins7093818","article-title":"Botulinum toxin type A as a therapeutic agent against headache and related disorders","volume":"7","author":"Luvisetto","year":"2015","journal-title":"Toxins"},{"key":"2021050313323209200_R14","volume-title":"Levels of Cognitive Functioning. Rehabilitation of the Head Injured Adult: Comprehensive Physical Management","author":"Hagen","year":"1999"},{"issue":"6","key":"2021050313323209200_R15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"2021050313323209200_R16","article-title":"The PTSD checklist: reliability, validity, and diagnostic utility","author":"Weathers"},{"key":"2021050313323209200_R17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0304-3959(94)90133-3","article-title":"What is the maximum number of levels needed in pain intensity measurement?","volume":"58","author":"Jensen","year":"1994","journal-title":"Pain"},{"issue":"8","key":"2021050313323209200_R18","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1026119331193","article-title":"A six-item short-form survey for measuring headache impact: the HIT-6","volume":"12","author":"Kosinski","year":"2003","journal-title":"Qual Life Res"},{"issue":"1","key":"2021050313323209200_R19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1179\/2042618613Y.0000000053","article-title":"Chronic post-traumatic headache: clinical findings and possible mechanisms","volume":"22","author":"Defrin","year":"2014","journal-title":"J Man Manip Ther"},{"issue":"8","key":"2021050313323209200_R20","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/ene.13657","article-title":"Prospective real-world analysis of onabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal","volume":"25","author":"Andreou","year":"2018","journal-title":"Eur J Neurol"},{"issue":"3","key":"2021050313323209200_R21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/head.12495","article-title":"Onabotulinum toxin A for the treatment of headache in service members with a history of mild traumatic brain injury: a cohort study","volume":"55","author":"Yerry","year":"2015","journal-title":"Headache"},{"issue":"6","key":"2021050313323209200_R22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.5114\/ninp.2012.32109","article-title":"Botulinum toxin in the treatment of post-traumatic headache \u2013 case study","volume":"46","author":"Lippert-Gr\u00fcner","year":"2012","journal-title":"Neurol Neurochir Pol"},{"issue":"2","key":"2021050313323209200_R23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/mdc3.12235","article-title":"OnabotulinumtoxinA and abobotulinumtoxinA dose conversion: a systematic literature review. Version 3","volume":"3","author":"Dashtipour","year":"2016","journal-title":"Mov Disord Clin Pract"},{"key":"2021050313323209200_R24","doi-asserted-by":"publisher","DOI":"10.3390\/toxins8030065","article-title":"Conversion ration between Botox\u00ae, Dysport\u00ae, and Xeomin\u00aein clinical practice","volume":"8","author":"Scaglione","year":"2016","journal-title":"Toxins"},{"issue":"Suppl 1","key":"2021050313323209200_R25","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1046\/j.1526-4610.43.7s.3.x","article-title":"Evidence for antinociceptive activity of botulinum toxin type A in pain management","volume":"43","author":"Aoki","year":"2003","journal-title":"Headache"},{"issue":"5","key":"2021050313323209200_R26","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/ane.12906","article-title":"Botulinum toxin: a review of the mode of action in migraine","volume":"137","author":"Do","year":"2018","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"2021050313323209200_R27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4610.2004.04007.x","article-title":"Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy","volume":"44","author":"Durham","year":"2004","journal-title":"Headache"},{"key":"2021050313323209200_R28","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/jnnp-2013-307149","article-title":"Percent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT","volume":"86","author":"Silberstein","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021050313323209200_R29","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s10072-017-3054-y","article-title":"Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting","volume":"38","author":"Santoro","year":"2017","journal-title":"Neurol Sci"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/186\/5-6\/493\/37774603\/usaa391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/186\/5-6\/493\/37774603\/usaa391.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T13:34:07Z","timestamp":1620048847000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/186\/5-6\/493\/6006401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":29,"journal-issue":{"issue":"5-6","published-online":{"date-parts":[[2021,5,3]]},"published-print":{"date-parts":[[2021,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usaa391","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,5,1]]}}}